Isidora Arsenovic

Isidora Arsenovic

Auto-generated profile, based on publicly available information

Isidora Arsenovic

University Clinical Center of Serbia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2025 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
DLDanijela Leković
Danijela Leković
ABAndrija Bogdanovic
Andrija Bogdanovic
IAIsidora Arsenovic
Isidora Arsenovic
JIJelena Ivanović
Jelena Ivanović
MČMirjana Čučaković
Mirjana Čučaković
IKIvan Krecak
Ivan Krecak
Standard ELN risk stratification for thrombosis and overall survival (OS) in patients with polycythemia vera (PV) is based on advanced age and history of thrombosis. Recently, the triple A (AAA) risk model was developed for OS prediction in patients with essential thrombocythemia, which, besides rising age, incorporates high (≥8x109/L) absolute neutrophil and low(<1.7 × 109/L) lymphocyte counts. The presented multicenter international study on a large cohort of PV patients validated the findings from prior reports and demonstrated excellent prognostic properties of the triple A model with respect to both thrombosis and survival in PV. Moreover, it revealed that the addition of patient comorbidities (assessed through the Charlson comorbidity index (CCI)) to ELN and triple A score may not help to further refine the survival prognostication of these patients. Therefore, the triple A score with its simplicity seems to offer excellent balance during the initial risk assessment in PV, implicating its global applicability.

19 June 2025 in Expert Review of Hematology
Verified
Journal Article
Closed access
IAIsidora Arsenovic
Isidora Arsenovic
NMNatasa Milic
Natasa Milic
NGNikola Grubor
Nikola Grubor
JJJelica Jovanovic
Jelica Jovanovic
IKIvan Krecak
Ivan Krecak
DLDanijela Lekovic
Danijela Lekovic
Thrombosis is a major complication in polycythemia vera (PV), contributing to significant morbidity and mortality. This retrospective study aimed to develop a predictive model for thrombosis risk in PV patients using advanced statistical techniques. The study included 817 consecutive PV patients, with a median follow-up of 59 months. A Bayesian logistic regression model with sparsity-inducing R2D2 priors was used to predict thrombosis. Thrombotic events occurred in 13.2% of patients. The thrombosis group had significantly higher median neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), splenomegaly, cardiovascular risk factors, microvascular symptoms, pruritus, previous thrombosis, and Charlson Comorbidity Index (CCI) compared to the no-thrombosis group. Both groups were comparable in age. Multivariate regression analysis identified CCI, PLR, splenomegaly, and microvascular symptoms as key predictors of thrombosis. A clinical score, ThromboVera CS, was developed based on these predictors, classifying patients into low, moderate, or high-risk groups. In the low-risk group, 6.94% experienced thrombosis, compared to 15.76% in moderate-risk group and 48.78% in the high-risk group. The ThromboVera CS score is a reliable, easy-to-use tool for predicting thrombosis in PV patients. It can help clinicians identify those at high risk, enabling early intervention that could significantly improve patient outcomes by targeting nearly 50% of high-risk patients.

17 August 2026 in Therapeutic Advances in Hematology
Verified
Journal Article
Open access
DLDanijela Leković
Danijela Leković
IAIsidora Arsenovic
Isidora Arsenovic
MČMirjana Čučaković
Mirjana Čučaković
DMDragan Mihailo Matic
Dragan Mihailo Matic
MLMilica Stojkovic Lalosevic
Milica Stojkovic Lalosevic
ABAndrija Bogdanovic
Andrija Bogdanovic
Background: In myeloproliferative neoplasms (MPNs), fibrosis occurs not only in the bone marrow but also in extramedullary organs such as the liver and spleen, reflected by increased tissue stiffness. Patients with MPNs frequently present with echocardiographic signs of cardiac dysfunction, which may be modifiable through targeted therapy. Objectives: To evaluate changes in organ stiffness and cardiac function in patients with myelofibrosis (MF) treated with ruxolitinib at baseline, 6, and 12 months. Methods: This prospective, single-center cohort study enrolled 30 MF patients diagnosed according to the current WHO criteria. At each assessment, clinical and laboratory parameters were evaluated, and abdominal ultrasound with shear wave elastography was performed to measure spleen and liver stiffness, alongside echocardiographic evaluation of cardiac function. Results: The median age of patients was 50 years (range, 21–76). After 6 months of treatment, both liver size (p=0.049) and spleen size (p<0.001) significantly decreased, accompanied by reduced liver and spleen stiffness, while echocardiographic parameters remained unchanged. Significant decreases were also observed in hemoglobin (p=0.017), absolute neutrophil count (p=0.025), platelets (p=0.003), neutrophil-to-lymphocyte ratio (p=0.007), and platelet-to-lymphocyte ratio (p=0.04). Patients reported a notable reduction in symptom burden. At 12 months, organ diameters and stiffness remained stable. Echocardiography demonstrated improved systolic pulmonary artery pressure (sPAP) with a significant difference compared with baseline (p<0.001), while NT-proBNP levels decreased by 50%. Laboratory parameters were largely stable, except for a significant decrease of lactate dehydrogenase. Ruxolitinib was initiated earlier in primary MF, but no significant differences between primary and secondary MF were observed regarding organ stiffness or cardiac findings after 12 months. Conclusion: Ruxolitinib demonstrated its greatest benefit at 6 months, significantly reducing organ size, stiffness, and symptom burden, followed by cardiovascular improvement and normalization of sPAP by 12 months. Further larger prospective studies with longer follow up are needed for definitive conclusion.